Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.

MLA

Melchor, Javier, et al. “Venetoclax Improves CD20 Immunotherapy in a Mouse Model of MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma.” Journal for Immunotherapy of Cancer, vol. 11, no. 2, Feb. 2023. EBSCOhost, https://doi.org/10.1136/jitc-2022-006113.

APA

Melchor, J., Garcia-Lacarte, M., Grijalba, S. C., Arnaiz-Leché, A., Pascual, M., Panizo, C., Blanco, O., Segura, V., Novo, F. J., Valero, J. G., Pérez-Galán, P., Martinez-Climent, J. A., & Roa, S. (2023). Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. Journal for Immunotherapy of Cancer, 11(2). https://doi.org/10.1136/jitc-2022-006113

Chicago

Melchor, Javier, Marcos Garcia-Lacarte, Sara C Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, et al. 2023. “Venetoclax Improves CD20 Immunotherapy in a Mouse Model of MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma.” Journal for Immunotherapy of Cancer 11 (2). doi:10.1136/jitc-2022-006113.